Illumina and Celgene could exit genome researcher Human Longevity in a reverse merger while Openly raised $75m from investors including Advance Venture Partners and Gradient Ventures.

Public markets

US-based genome researcher Human Longevity has signed a letter of intent to execute a reverse merger with special purpose acquisition company Freedom Acquisition 1. The non-binding deal would involve the combined business taking Freedom Acquisition 1’s listing on the New York Stock Exchange and would come after $330m in funding from investors including genomics technology producer Illumina, pharmaceutical firm Celgene and GE Ventures, the now shuttered investment arm of power and industrial equipment manufacturer General Electric.

.fadeOut{ background: rgb(255,255,255); background: linear-gradient(0deg, rgba(255,255,255,1) 0%, rgba(255,255,255,0) 100%); margin-top:-350px; position: relative; z-index: 10; margin-bottom:30px; padding:50px; } .flex{ display:flex; justify-content:space-between; padding:10px 15px; background:#2e71b6; align-items:center; } .restricted-content{ box-shadow:0px 10px 20px rgba(0,0,0,0.4); padding:30px !important; } @media(max-width:1024px){ .hiddenWrap{ position: relative; height:800px; overflow:hidden; } .fadeOut{ padding-right:10px; padding-left:10px; margin-top:40px; height:auto; width:100%; height:800px; position: absolute; top:0px; left:0px; } .flex{ display: block; text-align:center; } .flex button{ margin-top:10px; } .restricted-content{ position: absolute; top:0px; left:0px; width:100%; height:auto; position: relative; } }

Subscribe to go deeper

GCV subscribers get access to all our proprietary data and deep-dive articles, as well as the global directory of CVC investors.



Not sure if you have a subscription?